These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3536529)

  • 1. Therapeutic equivalence of once- and thrice-daily glipizide.
    Wåhlin-Boll E; Groop L; Karhumaa S; Groop PH; Tötterman KJ; Melander A
    Eur J Clin Pharmacol; 1986; 31(1):95-9. PubMed ID: 3536529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Acta Med Scand Suppl; 1981; 656():11-8. PubMed ID: 7046346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
    Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
    Scheen AJ; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
    Rosenstock J; Meisel A; Raskin P
    Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide.
    Jaber LA; Wenzloff NJ; Komanicky P; Antal EJ
    J Clin Pharmacol; 1990 Feb; 30(2):181-8. PubMed ID: 2107214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Duration of effective hypoglycaemic action of glipizide given once daily (author's transl)].
    Azzopardi J; Campbell IW; Clarke BF; Duncan LJ
    Med Klin; 1975 Jul; 70(28-29):1214-8. PubMed ID: 809650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.
    Shank ML; Del Prato S; DeFronzo RA
    Diabetes; 1995 Feb; 44(2):165-72. PubMed ID: 7859936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of glucose and lactate after intravenous glipizide administration in some insulin-dependent diabetics. Therapeutic effects of an associated glipizide-insulin treatment.
    Giampietro O; Navalesi R; Buzzigoli G; Boni C
    Curr Med Res Opin; 1979; 6(5):325-30. PubMed ID: 396109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of first-generation sulfonylureas and glipizide in non-insulin-dependent diabetes mellitus.
    Beisswenger PJ; Dias N; Beckman F
    Am J Med; 1987 Sep; 83(3A):16-21. PubMed ID: 3631118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-term insulin therapy upon therapeutic response to glipizide.
    Schwartz SL; Fischer JS; Kipnes MS; Boyle M
    Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
    Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
    Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
    Simpson HC; Sturley R; Stirling CA; Reckless JP
    Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of glipizide.
    Feinglos MN; Lebovitz HE
    Am J Med; 1983 Nov; 75(5B):60-6. PubMed ID: 6369969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime.
    Ostman J; Christenson I; Jansson B; Weiner L
    Acta Med Scand; 1981; 210(3):173-80. PubMed ID: 7027750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of glipizide.
    Melander A; Wåhlin-Boll E
    Am J Med; 1983 Nov; 75(5B):41-5. PubMed ID: 6424440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.